drugset / Trial / NCT03719430
APX005M and Doxorubicin in Advanced Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
Timeline
- Start
- 2019-03-20
- Primary completion
- 2025-12-11
- Completion
- 2025-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | sotigalimab | Monoclonal antibody | 0.3 mg/kg | Intravenous |